GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Core Insights - GenScript Biotech Corporation reported exceptional interim results for H1 2025, achieving consolidated revenue of approximately US$518.8 million, reflecting an 81.9% year-over-year increase, and demonstrating strong operational leverage and margin resilience [2][9] Financial Performance - Gross profit rose 140.1% to US$320.6 million, while adjusted net profit from continuing operations surged 509.6% to US$178 million, indicating rapid growth and superior profitability [2][9] - The Life Science Services and Products segment generated US$247.6 million in revenue, an 11.3% increase year-over-year, with the protein business experiencing a remarkable 52% uplift [4] - The biologics development CDMO services under ProBio reported US$246.9 million in revenue, a 511.1% increase year-over-year, with adjusted gross margin expanding to 73.6% [5][9] Strategic Growth Drivers - The company is committed to deepening R&D investment, expanding production capacity, and accelerating market penetration to deliver sustainable growth and superior value [4] - Bestzyme, the industrial synthetic biology products unit, grew its revenue by 8.4%, driven by market share gains and innovative enzyme portfolio [6] - GenScript's global production and R&D footprint supports over 60% automation penetration, enhancing supply chain resilience and responsiveness [10] ESG Commitment - GenScript has received top-tier ESG ratings, including an MSCI AA rating and inclusion in the FTSE4Good Index Series, reinforcing its commitment to responsible growth [11][12] - The company’s science-based carbon reduction targets are validated by the SBTi, showcasing its alignment with global best practices in sustainability [11] Outlook - The company anticipates continued growth backed by scaling automation, global brand strength, and an expanding pipeline of innovative solutions, positioning itself to sustain biotech leadership [13]